{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-002864","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.904936+00:00","generated_at":"2026-06-15T21:35:30.784370+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arbutus Q1 rev down 47% to $6.7M; files patent suit vs Pfizer/BioNTech; AB-101 IND on hold","bullets":["Q1 revenue $6.7M vs $12.6M YoY; net loss $16.3M ($0.10/shr) vs $15.8M ($0.11) YoY.","Filed patent infringement lawsuit against Pfizer and BioNTech for COVID-19 LNP vaccine technology.","FDA placed AB-101 (oral PD-L1) IND on clinical hold; Phase 1 not initiated, no patients dosed.","Cash $178.5M; burn guidance reduced to $90-95M from $95-100M; runway into Q1 2025.","Dosed first subject in Phase 1 trial for AB-161 (oral RNA destabilizer); data expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-002864","json":"https://secwatch.observer/filing/0001171843-23-002864.json","markdown":"https://secwatch.observer/filing/0001171843-23-002864.md","text":"https://secwatch.observer/filing/0001171843-23-002864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323002864/0001171843-23-002864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323002864/f8k_050423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:35:30.784370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd3898aa4d0c69271b415590ea8b0d1b1366cf5a","claim":"Arbutus Biopharma Corp updated its first quarter ended March 31, 2023 guidance (lowered).","evidence_excerpt":"On May 4, 2023, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023 and certain other information.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323002864/0001171843-23-002864-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}